BridgeBio Pharma Balance Sheet Health
Financial Health criteria checks 1/6
BridgeBio Pharma has a total shareholder equity of $-1.0B and total debt of $1.7B, which brings its debt-to-equity ratio to -165.5%. Its total assets and total liabilities are $849.3M and $1.9B respectively.
Key information
-165.5%
Debt to equity ratio
US$1.72b
Debt
| Interest coverage ratio | n/a |
| Cash | US$519.69m |
| Equity | -US$1.04b |
| Total liabilities | US$1.89b |
| Total assets | US$849.33m |
Recent financial health updates
No updates
Recent updates
BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Nov 06
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jul 02New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
May 09Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook
Feb 28Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts
Jan 09BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status
Oct 11BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU
Sep 20BridgeBio Pharma: Down But Not Out
Aug 31BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders
Aug 18Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%
Aug 10BridgeBio Pharma GAAP EPS of -$0.07 beats by $0.65, revenue of $73.75M beats by $48.75M
Aug 04BridgeBio, Sentynl's Nulibry get EMA panel nod for approval in EU
Jul 25BridgeBio Pharma: Yet To Be Proven Business Model
Jun 09News Flash: Analysts Just Made A Dazzling Upgrade To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Forecasts
May 22Financial Position Analysis
Short Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BBIO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BBIO has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BBIO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BBIO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BBIO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 17.6% each year.